CADET® BRAF and
CADET® BRAF-PLUS

Accurate canine bladder and prostate cancer test

CB 01 Dskt

The power of molecular diagnostics

CADET® BRAF evaluates urine samples from dogs for the presence of cells containing a mutation for canine bladder/prostate cancer (TCC/UC). It’s cutting-edge technology that is accurate, affordable, and convenient for both veterinarian and pet owner.

Download the Test Request Form
CB 02 Dskt

Achieve accurate and early diagnosis of TCC/UC

CADET® BRAF is a highly sensitive test designed to monitor the b-raf mutation in TCC/UC cases during the course of their treatment, for therapeutic response and relapse. CADET® BRAF testing can be used for both the rapid, non-invasive assessment of dogs displaying clinical signs consistent with TCC/UC and for confirmed cases undergoing treatment.

How it Works

How CADET® BRAF is
used in a clinical setting

CADET® BRAF evaluates free-catch urine samples from dogs for the presence of cells harboring the BRAF mutation or specific copy number variations associated with TCC/UC. The assays identify 95% of TCC/UC cases. The extremely low limit of detection of 10 mutation-bearing cells in a urine sample allows early diagnosis of a developing TCC/UC, often several months before any advanced clinical signs associated with the cancer become evident.

CB 03 Mb

CADET® BRAF-PLUS

CADET® BRAF-PLUS provides further evaluation of those dogs that present with clinical signs consistent with TCC/UC, but for which no BRAF mutation is detected. Our comprehensive analysis of thousands of clinical specimens has shown that CADET® BRAF-PLUS detects more than 2/3 of the TCC/UC cases that are not identified by CADET® BRAF.

Clinical indications for when to use CADET® BRAF and BRAF-PLUS

Clinical cases presenting with hematuria, stranguria, and/or urinary incontinence with diagnostic imaging evidence of a mass in the bladder.
During chemotherapy to monitor treatment success by decreased levels of BRAF mutation detection, or to monitor cancer relapse by recurrence of BRAF mutation tumor-bearing cells.
Early diagnosis in clinical cases with recurrent, complicated, or antibiotic-resistant urinary tract infections presenting with hematuria without ultrasonographic evidence of a bladder mass.
Confirmation of the TCC/UC diagnosis of a bladder mass from a stained cytology slide following ultrasonography and cytological examination of a fine-needle aspirate from tumor-bearing cells.
Early detection in high-risk dog breeds such as terriers, Shetland and Australian sheep dogs, cattle dogs, beagles, and border collies that are 6 years and older.
Innovations

The Canine
CE-IBD Assay

Introducing the first diagnostic of its kind

Learn More

Sign up to learn
more about
CADET® BRAF and BRAF-PLUS

FIRSTTRACT Annoucement
Innovations
Close
FIRSTract™ Urine Culture
The new gold standard for rapid detection of bacteria in urine
Learn More

We use cookies to personalize content and ads, to provide social media features and to analyze our traffic. See our cookie policy.

Close